VWA
GLUE icon

Valued Wealth Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

Valued Wealth Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$944 Buy
+39
New +$737 ﹤0.01% 784

Other funds holding GLUE

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM
MFA
Mayflower Financial Advisors Boston, Massachusetts $1.16B AUM 24.36% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Valued Wealth Advisors's GLUE Position: Q2 2026 in Review

Valued Wealth Advisors opened a new position in Monte Rosa Therapeutics (GLUE) in Q2 2026: 39 shares worth $944. The stake represents ﹤0.01% of the portfolio and ranks #784 among its holdings.

18 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Valued Wealth Advisors held 39 shares of Monte Rosa Therapeutics worth $944 as of Q2 2026.
  • Monte Rosa Therapeutics was a new Valued Wealth Advisors position in Q2 2026.
  • Monte Rosa Therapeutics made up ﹤0.01% of Valued Wealth Advisors's portfolio in Q2 2026, its #784 holding.
  • 18 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Valued Wealth Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.